Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials

Review of 12 RCTs (n=5,457) found that adding oxaliplatin to adjuvant fluoropyrimidine significantly improved the overall survival and disease free survival in patients with microsatellite instability disease (HR 0.52, 95%CI 0.28-0.93).

Journal of Clinical Oncology